Irbesartan effects on renal function in patients with renal impairment and hypertension: A drug-withdrawal study

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 3, 2001, Pages 482-489

  De Rosa, Maria Leonarda ^a,b   De Cristofaro, Alessandro ^a   Rossi, Massimiliano ^a   Baiano, Antonio ^a   Cardace, Piercarmine ^a   Albanese, Luigi ^a   Vigorito, Carlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE   (Italy)

Author keywords

Angiotensin II; Irbesartan; Renal insufficiency; Reninangiotensin aldosterone system

Indexed keywords

ANTIHYPERTENSIVE AGENT; IRBESARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PLACEBOS; PROTEINURIA; TETRAZOLES;

EID: 0034891919     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200109000-00017     Document Type: Article

References (26)

1. Progression of renalinsufficiency: Role of blood pressure
2. Hypertension-related renal injury: A major contributor to end-stage renal disease
3. Impact of left ventricular hypertrophy on survival in end-stage renal disease
4. The effect of angiotensin-converting enzyme on diabetic nephropathy
5. Strict blood pressure control and progression of renal disease in hypertensive nephrosclerosis
6. Effect of enalapril on the progression of chronic renal failure: A randomized controlled trial
7. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease
8. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors
9. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension
10. Safety and efficacy of irbesartan in hypertensive patients with type 2 diabetes and proteinuria
11. Multicenter collaborative trial of angiotensin II receptor antagonism on morbidity, mortality and renal function in hypertensive type II diabetic patients with nephropathy
12. The renal clearance of alkali-stable inulin
13. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
14. The Sixth Report of The Joint National Committee. On prevention, detection, evaluation, and treatment of high blood pressure
15. Sympathetic overactivity in patients with chronic renal failure
16. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension
17. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes with non-diabetic renal diseases
18. Renal protective effect of enalapril in diabetic nephropathy
19. Randomized controlled trial of enalapril and β-blockers in non diabetic chronic renal failure
20. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis
21. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
22. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study
23. Safety of the combination of valsartan and benazepril in patients with chronic renal disease
24. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure
25. Disorders of potassium balance
26. Hematologic consequence of renal failure